William Blair Has Bullish Outlook for LENZ FY2024 Earnings

LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Analysts at William Blair increased their FY2024 EPS estimates for LENZ Therapeutics in a research note issued to investors on Wednesday, November 6th. William Blair analyst L. Hanbury-Brown now anticipates that the company will post earnings of ($2.28) per share for the year, up from their prior forecast of ($2.44). William Blair currently has a "Strong-Buy" rating on the stock. The consensus estimate for LENZ Therapeutics' current full-year earnings is ($2.09) per share. William Blair also issued estimates for LENZ Therapeutics' Q4 2024 earnings at ($0.41) EPS, Q1 2025 earnings at ($0.48) EPS, Q2 2025 earnings at ($0.69) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.97) EPS and FY2025 earnings at ($2.87) EPS.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.09. During the same period in the previous year, the company posted ($1.33) earnings per share.

Several other equities research analysts have also recently issued reports on the company. HC Wainwright reissued a "buy" rating and set a $38.00 target price on shares of LENZ Therapeutics in a research note on Thursday. Raymond James started coverage on LENZ Therapeutics in a research note on Friday, September 27th. They issued an "outperform" rating and a $37.00 price objective on the stock. Finally, Piper Sandler reissued an "overweight" rating and issued a $36.00 price objective on shares of LENZ Therapeutics in a research report on Thursday, August 15th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $35.40.

LENZ Therapeutics Price Performance

Shares of LENZ Therapeutics stock traded up $0.68 during trading hours on Monday, reaching $35.75. 184,455 shares of the company's stock were exchanged, compared to its average volume of 136,713. The business has a fifty day moving average of $24.94 and a two-hundred day moving average of $21.27. LENZ Therapeutics has a 1 year low of $14.07 and a 1 year high of $37.13.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. American International Group Inc. purchased a new position in LENZ Therapeutics during the 1st quarter worth $44,000. SG Americas Securities LLC purchased a new position in LENZ Therapeutics during the third quarter worth about $107,000. GSA Capital Partners LLP acquired a new stake in LENZ Therapeutics in the third quarter valued at about $246,000. Squarepoint Ops LLC purchased a new stake in LENZ Therapeutics in the 2nd quarter valued at approximately $181,000. Finally, BNP Paribas Financial Markets acquired a new position in LENZ Therapeutics during the 1st quarter worth approximately $362,000. Institutional investors and hedge funds own 54.32% of the company's stock.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.